Loading...
Please wait, while we are loading the content...
Similar Documents
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma
| Content Provider | Scilit |
|---|---|
| Author | Chadha, Awalpreet Gunther, Jillian R. Hsieh, Cheng-En Aliru, Maureen Mahadevan, Lakshmi S. Venkatesulu, Bhanu P. Crane, Christopher H. Das, Prajnan Herman, Joseph M. Koay, Eugene J. Taniguchi, Cullen Holliday, Emma B. Minsky, Bruce D. Suh, Yelin Park, Peter Sawakuchi, Gabriel Beddar, Sam Odisio, Bruno C. Gupta, Sanjay Loyer, Evelyne Kaur, Harmeet Raghav, Kanwal Javle, Milind M. Kaseb, Ahmed O. Krishnan, Sunil |
| Copyright Year | 2019 |
| Description | Journal: Radiotherapy and Oncology Background and purpose This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized unresectable hepatocellular carcinoma (HCC). Methods and methods Forty-six patients with HCC, Child-Pugh class of A or B, no prior radiotherapy history, and ECOG performance status 0–2 received PBT at our institution from 2007 to 2016. Radiographic control within the PBT field (local control, LC) and overall survival (OS) were calculated from the start of PBT. Results Most (83%) patients had Child-Pugh class A. Median tumor size was 6 cm (range, 1.5–21.0 cm); 22% of patients had multiple tumors and 28% had tumor vascular thrombosis. Twenty-five (54%) patients received prior treatment. Median biologically effective dose (BED) was 97.7 GyE (range, 33.6–144 GyE) administered in 15 fractions. Actuarial 2-year LC and OS rates were 81% and 62% respectively; median OS was 30.7 months. Out-of-field intrahepatic failure was the most common site of disease progression. Patients receiving BED ≥90 GyE had a significantly better OS than those receiving BED <90 GyE (49.9 vs. 15.8 months, p = 0.037). A trend toward 2-year LC improvement was observed in patients receiving BED ≥90 GyE compared with those receiving BED <90 GyE (92% vs. 63%, p = 0.096). On multivariate analysis, higher BED (p = 0.023; hazard ratio = 0.308) significantly predicted improved OS. Six (13%) patients experienced acute grade 3 toxicity. Conclusions High-dose PBT is associated with high rates of LC and OS for unresectable HCC. Dose escalation may further improve outcomes. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446916/pdf http://www.thegreenjournal.com/article/S0167814018336727/pdf |
| Ending Page | 61 |
| Page Count | 8 |
| Starting Page | 54 |
| ISSN | 01678140 |
| e-ISSN | 18790887 |
| DOI | 10.1016/j.radonc.2018.10.041 |
| Journal | Radiotherapy and Oncology |
| Volume Number | 133 |
| Language | English |
| Publisher | Elsevier BV |
| Publisher Date | 2019-04-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Radiotherapy and Oncology Gastroenterology and Hepatology Proton Radiation; Primary Liver Cancer; Dose Escalation |
| Content Type | Text |
| Resource Type | Article |
| Subject | Radiology, Nuclear Medicine and Imaging Hematology Oncology |
